This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): HuMax-EGFr
Description: HuMax-EGFr is a fully human antibody targeting the Epidermal Growth Factorreceptor, or EGFr. EGFr is a receptor molecule that has been found in excess on many tumor cells, including carcinoma of the head and neck, breast, colon, prostate, lung and ovary.
Deal Structure: Medarex received an equity interest in Genmab in exchange for a license of its proprietary antibody technology. It is not entitled to license fees, milestone payments or royalties from the license of this particular product candidate (zalutumumab).
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash.
In September 2009, Bristol-Myers Squibb completed its acquisition of Medarex.
Partners: Bristol-Myers Squibb Company
Additional information available to subscribers only: